15 April 2015Americas

PTAB instigates interference on Biogen multiple sclerosis treatment

The US Patent Trial and Appeal Board (PTAB) has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis (MS).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk